止血剤の世界市場 - 2025年～2032年

止血剤の世界市場は2024年に30億1,000万米ドルに達し、2032年には41億5,000万米ドルに達すると予測され、予測期間2025年～2032年のCAGRは4.2%で成長する見込みです。

止血剤は、創傷部や手術部位の出血を予防または止血するために設計された物質です。止血剤は、出血を止めるための身体のメカニズムである止血中に起こる自然なプロセスを促進することによって機能します。止血剤は血漿タンパク質、カルシウムイオン、血小板と相互作用し、血栓形成を促進し、出血をコントロールします。

止血剤はこのフィブリノゲンからフィブリンへの変換を促進し、より効率的で耐久性のある血栓を確保します。止血剤は、外科手術や外傷治療、出血のコントロールが重要な医療処置の際に一般的に使用され、より迅速で確実な止血を促進する重要な助けとなります。

市場力学：

促進要因と抑制要因

手術件数の増加

世界の外科手術件数の増加は、止血剤市場を牽引する重要な要因です。手術件数の増加に伴い、複雑な手術中の出血をコントロールする効果的な止血剤へのニーズが高まっています。この動向は、しばしば外科的治療を必要とする心血管系疾患やがんなどの慢性疾患の有病率の上昇によってさらに拍車がかかっています。例えば、2023年の米国国立衛生研究所（National Institute of Health）によると、CABG手術は毎年40万件近く行われており、最も一般的に行われている大手術です。

手術を受ける患者が増えるにつれて、信頼性の高い止血ソリューションの需要は伸び続け、市場の拡大に寄与しています。例えば、2024年の米国国立衛生研究所によると、人工股関節全置換術と人工膝関節全置換術は米国で最も一般的に行われている手術の2つであり、推定700万人の米国人が人工股関節全置換術または人工膝関節全置換術を受けて生活しており、毎年100万件以上の人工股関節全置換術と人工膝関節全置換術が行われています。

ジェル、ドレッシング材、パウダーなどの止血剤は、このような手技における止血をサポートするためにますます使用されるようになっており、現代の外科診療において不可欠な要素となっています。効果的な止血の必要性、特に高い精度と迅速な回復を必要とする手術において、これらの薬剤は手術における重要な構成要素となっています。したがって、手術手技が進化し続け、手術件数が世界的に増加するにつれて、止血剤の市場は急速に拡大すると予想されます。

止血剤に関連する有害な副作用

止血剤に関連する有害な副作用は、患者の安全性と治療効果に対する懸念を引き起こし、市場成長の大きな課題となっています。これらの薬剤は、頭痛、吐き気、呼吸器系の問題、アナフィラキシーのような重篤なアレルギー反応を含む様々な副作用を引き起こす可能性があり、医療従事者の使用意欲を減退させる可能性があります。さらに、これらの製剤の不適切な適用や過剰使用によって、感染症や組織損傷などの合併症が起こる可能性があり、手術成績を複雑にし、より広範な採用を制限します。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 慢性疼痛疾患の罹患率の増加
  • 抑制要因
    • 止血剤に関連する副作用と安全性の懸念
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 材料別

• キトサンベース
• ゼラチンベース
• コラーゲンベース
• 酸化再生セルロース（ORC）
• 流動性止血材
• その他

第7章 形態別

• 粉末
• ゲル
• スポンジ
• マトリックス
• シート＆パッド

第8章 投与経路別

• 局所
• 静脈内
• その他

第9章 用途別

• 一般外科
• 心臓血管外科
• 整形外科
• その他

第10章 エンドユーザー別

• 病院
• クリニック
• 診断検査室
• その他

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第12章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第13章 企業プロファイル

• Becton, Dickinson, and Company
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Aegis Lifesciences
• Baxter
• Teleflex Incorporated
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• 3-D Matrix Medical Technology
• Medcura
• Ferrosan Medical Devices A/S
• Delta Surgical

第14章 付録

第15章 問い合わせ

The global hemostatic agents market reached US$ 3.01 billion in 2024 and is expected to reach US$ 4.15 billion by 2032, growing at a CAGR of 4.2% during the forecast period 2025-2032.

Hemostatic agents are substances designed to help prevent or stop bleeding at a wound or surgical site. They work by facilitating the natural processes that occur during hemostasis, which is the body's mechanism for stopping bleeding. Hemostatic agents interact with plasma proteins, calcium ions, and blood platelets to promote clot formation and control bleeding.

Hemostatic agents enhance this fibrinogen-to-fibrin conversion, ensuring a more efficient and durable clot. These agents are commonly used in surgical settings, trauma care, and during medical procedures where bleeding control is critical, providing a crucial aid in promoting faster and more reliable hemostasis.

Market Dynamics: Drivers & Restraints

Increasing Surgical Volume

The growing number of surgical procedures worldwide is a key factor driving the hemostatic agents market. As surgical volumes rise, there is an increasing need for effective hemostatic agents to control bleeding during complex surgeries. This trend is further fueled by the rising prevalence of chronic conditions, such as cardiovascular diseases and cancer, that often require surgical treatment. For instance, the National Institute of Health in 2023 stated that almost 400,000 CABG surgeries are performed each year making it the most commonly performed major surgical procedure.

As more patients undergo surgery, the demand for reliable hemostatic solutions continues to grow, contributing to the market's expansion. For instance, according to the National Institute of Health in 2024, total hip and knee arthroplasty surgeries are two of the most common procedures performed in the United States, with an estimated 7 million Americans living with a total hip or knee replacement and over 1 million total hip and knee replacements performed each year.

Hemostatic agents, such as gels, dressings, and powders, are increasingly being used to support hemostasis in these procedures, making them an essential component in modern surgical practices. The need for effective hemostasis, especially in surgeries requiring high precision and quick recovery, is making these agents important components in surgeries. Thus, as surgical techniques continue to evolve and surgical volumes increase worldwide, the market for hemostatic agents is expected to expand rapidly

Adverse Effects Associated with the Hemostatic Agents

Adverse effects associated with hemostatic agents pose a significant challenge to their market growth, raising concerns about patient safety and treatment effectiveness. These agents can lead to various side effects, including headaches, nausea, respiratory issues, and potentially severe allergic reactions such as anaphylaxis, which may discourage healthcare providers from using them. Furthermore, complications like infections and tissue damage can occur from improper application or overuse of these products, complicating surgical outcomes and limiting their broader adoption.

Segment Analysis

The global hemostatic agents market is segmented based on material, form, route of administration, application, end-user, and region.

Type:

Chitosan-based segment is expected to dominate the global hemostatic agents market share

Chitosan-based hemostatic agents segment is expected to hold a dominant position in the hemostatic agents market due to several key factors. Chitosan's unique biocompatibility, tunable mechanical properties, and ease of handling make it an ideal choice for use in hemostatic applications. Its injectability allows for minimally invasive procedures, which enhances its appeal in various surgical settings.

Chitosan-based hemostatic hydrogels are commonly used for controlling bleeding due to their exceptional biocompatibility, adjustable mechanical properties, injectability, and ease of use. Additionally, chitosan (CS) can absorb red blood cells and stimulate platelet activation, enhancing the process of hemostasis. The growing demand for natural and biocompatible materials in healthcare, along with its proven efficacy in controlling bleeding during surgeries, positions chitosan-based hemostatic agents as a leading solution in the market. Additionally, advancements in chitosan-based formulations are further driving the segment's growth, making it a preferred choice for healthcare providers.

Geographical Analysis

North America is expected to hold a significant position in the global hemostatic agents market share

North America is expected to hold a significant position in the global hemostatic agents market due to several high rates of surgical procedures which include both elective and emergency surgeries, leading to higher demand for hemostatic agents to control bleeding during and after these procedures. For instance, according to the National Institute of Health report in 2023, in the United States, 1 in 9 individuals living in households reported having at least one surgical procedure in 2023. The highest rates were observed among individuals aged 65 and older, as well as Medicare beneficiaries, with approximately 1 in 5 people in both groups reporting having undergone surgery.

The growing prevalence of chronic conditions like cardiovascular diseases, diabetes, and cancer, all which increase the demand for effective hemostatic solutions. Furthermore, North America comprises several key market players and a strong focus on medical innovation, leading to the development and adoption of cutting-edge hemostatic products. For instance, in July 2023, Baxter International Inc. launched the PERCLOT Absorbable Hemostatic Powder in the U.S. PERCLOT is a passive, absorbable hemostatic powder that is ready to use and designed for patients with intact coagulation to address mild bleeding. The region also has well-established regulatory frameworks, which ensure the safety and effectiveness of these agents, further boosting their use.

Competitive Landscape

The major global players in the hemostatic agents market include Becton, Dickinson, and Company, Aegis Lifesciences, Baxter, Teleflex Incorporated, Johnson & Johnson Services, Inc., Pfizer Inc., 3-D Matrix Medical Technology, Medcura, Ferrosan Medical Devices A/S and Delta Surgical among others.

Key Developments

• In April 2023, Olympus announced the launch of EndoClot Adhesive (ECA), EndoClot Polysaccharide Hemostatic Spray (PHS) and EndoClot Submucosal Injection Solution (SIS) in the Europe, Middle East and Africa (EMEA) region. This innovative portfolio was developed by EndoClot Plus, Inc. (EPI), which expanded its distribution agreement with Olympus from the U.S. to EMEA in December 2022.
• In September 2024, Toagosei Co., Ltd. launched a dental hemostatic agent for tooth extraction sockets called "Aron Cure Dental". Aron Cure Dental is a new concept of dental hemostatic agent. It stops bleeding after tooth extraction with a hydrogel polymer sponge.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Hemostatic Agents market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Material
• 3.2. Snippet by Form
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Application
• 3.5. Snippet by End-User
• 3.6. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing prevalence of chronic pain conditions
  • 4.1.2. Restraints
    • 4.1.2.1. Adverse effects and safety concerns associated with Hemostatic Agents
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Material

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Material
  • 6.1.2. Market Attractiveness Index, By Material
• 6.2. Chitosan-based*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Gelatine-based
• 6.4. Collagen-based
• 6.5. Oxidized Regenerated Cellulose (ORC)
• 6.6. Flowable Hemostats
• 6.7. Others

7. By Form

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pain Type
  • 7.1.2. Market Attractiveness Index, By Pain Type
• 7.2. Powder*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Gel
• 7.4. Sponges
• 7.5. Matrix
• 7.6. Sheet & Pads

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Topical*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Intravenous
• 8.4. Others

9. By Application

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.1.2. Market Attractiveness Index, By Application
• 9.2. General Surgery*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Cardiovascular Surgery
• 9.4. Orthopedic Surgery
• 9.5. Others

10. By End-User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.1.2. Market Attractiveness Index, By End-User
• 10.2. Hospitals*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Clinics
• 10.4. Diagnostic Laboratories
• 10.5. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.8.1. U.S.
    • 11.2.8.2. Canada
    • 11.2.8.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.8.1. Germany
    • 11.3.8.2. U.K.
    • 11.3.8.3. France
    • 11.3.8.4. Spain
    • 11.3.8.5. Italy
    • 11.3.8.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.8.1. Brazil
    • 11.4.8.2. Argentina
    • 11.4.8.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.8.1. China
    • 11.5.8.2. India
    • 11.5.8.3. Japan
    • 11.5.8.4. South Korea
    • 11.5.8.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Becton, Dickinson, and Company*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Aegis Lifesciences
• 13.3. Baxter
• 13.4. Teleflex Incorporated
• 13.5. Johnson & Johnson Services, Inc.
• 13.6. Pfizer Inc.
• 13.7. 3-D Matrix Medical Technology
• 13.8. Medcura
• 13.9. Ferrosan Medical Devices A/S
• 13.10. Delta Surgical

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services

15. Contact Us